BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 34916779)

  • 1. Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer.
    Yang YY; Zhang W; Liu H; Jiang JJ; Wang WJ; Jia ZY
    Drug Des Devel Ther; 2021; 15():4961-4972. PubMed ID: 34916779
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
    Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells.
    Zhang C; Yuan W; Wu Y; Wan X; Gong Y
    Life Sci; 2021 Feb; 266():118886. PubMed ID: 33310044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
    Werfel TA; Wang S; Jackson MA; Kavanaugh TE; Joly MM; Lee LH; Hicks DJ; Sanchez V; Ericsson PG; Kilchrist KV; Dimobi SC; Sarett SM; Brantley-Sieders DM; Cook RS; Duvall CL
    Cancer Res; 2018 Apr; 78(7):1845-1858. PubMed ID: 29358172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rictor promotes tumor progression of rapamycin-insensitive triple-negative breast cancer cells.
    Watanabe R; Miyata M; Oneyama C
    Biochem Biophys Res Commun; 2020 Oct; 531(4):636-642. PubMed ID: 32819718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel cell-penetrating peptide-loaded nanobubbles synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative Breast cancer therapy.
    Jing H; Cheng W; Li S; Wu B; Leng X; Xu S; Tian J
    Colloids Surf B Biointerfaces; 2016 Oct; 146():387-95. PubMed ID: 27388967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
    Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes.
    Mao S; Neu M; Germershaus O; Merkel O; Sitterberg J; Bakowsky U; Kissel T
    Bioconjug Chem; 2006; 17(5):1209-18. PubMed ID: 16984130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
    Lu ZX; Liu LT; Qi XR
    Int J Nanomedicine; 2011; 6():1661-73. PubMed ID: 21904456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
    Zhao Z; Li Y; Shukla R; Liu H; Jain A; Barve A; Cheng K
    Theranostics; 2019; 9(15):4508-4524. PubMed ID: 31285776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indole-2-Carboxamide Derivative LG25 Inhibits Triple-Negative Breast Cancer Growth By Suppressing Akt/mTOR/NF-κB Signalling Pathway.
    Xu X; Rajamanickam V; Shu S; Liu Z; Yan T; He J; Liu Z; Guo G; Liang G; Wang Y
    Drug Des Devel Ther; 2019; 13():3539-3550. PubMed ID: 31631978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasound-guided delivery of thymidine kinase-nitroreductase dual therapeutic genes by PEGylated-PLGA/PIE nanoparticles for enhanced triple negative breast cancer therapy.
    Devulapally R; Lee T; Barghava-Shah A; Sekar TV; Foygel K; Bachawal SV; Willmann JK; Paulmurugan R
    Nanomedicine (Lond); 2018 May; 13(9):1051-1066. PubMed ID: 29790803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of polyethylene glycol-grafted polyethylenimine and superparamagnetic iron oxide nanoparticles (PEG-g-PEI-SPION) as an MRI-visible vector for siRNA delivery in gastric cancer in vitro and in vivo.
    Chen Y; Lian G; Liao C; Wang W; Zeng L; Qian C; Huang K; Shuai X
    J Gastroenterol; 2013 Jul; 48(7):809-21. PubMed ID: 23179610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient and Tumor Targeted siRNA Delivery by Polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate (PEI-PCL-PEG-Fol).
    Liu L; Zheng M; Librizzi D; Renette T; Merkel OM; Kissel T
    Mol Pharm; 2016 Jan; 13(1):134-43. PubMed ID: 26641134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
    Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease.
    Liu YY; Yang XY; Li Z; Liu ZL; Cheng D; Wang Y; Wen XJ; Hu JY; Liu J; Wang LM; Wang HJ
    CNS Neurosci Ther; 2014 Jan; 20(1):76-85. PubMed ID: 24279586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional graphene oxide as a plasmid-based Stat3 siRNA carrier inhibits mouse malignant melanoma growth in vivo.
    Yin D; Li Y; Lin H; Guo B; Du Y; Li X; Jia H; Zhao X; Tang J; Zhang L
    Nanotechnology; 2013 Mar; 24(10):105102. PubMed ID: 23425941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.
    Gulhati P; Cai Q; Li J; Liu J; Rychahou PG; Qiu S; Lee EY; Silva SR; Bowen KA; Gao T; Evers BM
    Clin Cancer Res; 2009 Dec; 15(23):7207-16. PubMed ID: 19934294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2.
    Boulbes D; Chen CH; Shaikenov T; Agarwal NK; Peterson TR; Addona TA; Keshishian H; Carr SA; Magnuson MA; Sabatini DM; Sarbassov dos D
    Mol Cancer Res; 2010 Jun; 8(6):896-906. PubMed ID: 20501647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
    Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
    Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.